Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (449) Arrow Down
Filter Results: (449) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (637)
    • People  (2)
    • News  (57)
    • Research  (449)
    • Events  (2)
    • Multimedia  (8)
  • Faculty Publications  (395)

Show Results For

  • All HBS Web  (637)
    • People  (2)
    • News  (57)
    • Research  (449)
    • Events  (2)
    • Multimedia  (8)
  • Faculty Publications  (395)
← Page 7 of 449 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • March 1996
  • Case

Erox Corporation: Leverage Marketing

Erox Corp. is a biotechnology start-up that creates products containing synthetic human pheromones. It was founded in 1989, went public in 1993, and brought in a turnaround team in 1994. Sales ramped from $110,000 in 1993 to over $1 million in 1994, with prospects for... View Details
Keywords: Marketing Communications; Entrepreneurship; Biotechnology Industry
Citation
Educators
Purchase
Related
Kosnik, Thomas J. "Erox Corporation: Leverage Marketing." Harvard Business School Case 596-046, March 1996.
  • Research Summary

Overview

The research activity of Stefano Denicolai regards the management of innovation and technology. His recent works investigate if and how the investment in intangible assets (IA) - especially knowledge assets, such as patents or copyright - impacts on the firm... View Details
Keywords: Innovation Management; International Entrepreneurship; Intangible Assets; Open Innovation; Innovation and Management; Entrepreneurship; Competitive Strategy; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
  • February 2003
  • Article

Which Ties Matter When? The Contingent Effects of Interorganizational Partnerships on IPO Success

By: Ranjay Gulati and M. Higgins
This paper investigates the contingent value of interorganizational relationships at the time of a young firm's initial public offering (IPO). We compare the signaling value to young firms of having ties with two types of interorganizational partnerships: endorsement... View Details
Keywords: Interorganizatonal Relationships; Networks; Venture Capital; Initial Public Offering; Entrepreneurship; Biotechnology Industry
Citation
Find at Harvard
Related
Gulati, Ranjay, and M. Higgins. "Which Ties Matter When? The Contingent Effects of Interorganizational Partnerships on IPO Success." Strategic Management Journal 24, no. 2 (February 2003): 127–144.
  • April 2009
  • Case

GSK's Acquisition of Sirtris: Independence or Integration?

By: Toby E. Stuart and James Weber
An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science.... View Details
Keywords: Mergers and Acquisitions; Resource Allocation; Organizational Change and Adaptation; Organizational Culture; Organizational Structure; Research and Development; Science-Based Business; Integration
Citation
Educators
Purchase
Related
Stuart, Toby E., and James Weber. "GSK's Acquisition of Sirtris: Independence or Integration?" Harvard Business School Case 809-026, April 2009.
  • March 1992
  • Case

Amgen, Inc.: Planning the Unplannable

By: Nitin Nohria
By the early 1990s, Amgen--a pharmaceutical company started little over a decade ago as Applied Molecular Genetics--was within range of becoming a billion-dollar company. With two extremely successful biotechnology drugs on the market, Amgen stood as the largest and... View Details
Keywords: Growth and Development Strategy; Strategic Planning; Success; Risk and Uncertainty; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Nohria, Nitin. "Amgen, Inc.: Planning the Unplannable." Harvard Business School Case 492-052, March 1992.
  • April 2002
  • Case

In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen

By: Juan Enriquez-Cabot, Gary P. Pisano and Gaye Bok
Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed... View Details
Keywords: Change; Decisions; Product Development; Research and Development; Expansion; Technology; Biotechnology Industry
Citation
Educators
Purchase
Related
Enriquez-Cabot, Juan, Gary P. Pisano, and Gaye Bok. "In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen." Harvard Business School Case 602-122, April 2002.
  • July–August 2021
  • Article

Lowering the Bar? External Conditions, Opportunity Costs, and High-Tech Startup Outcomes

By: Annamaria Conti and Maria P. Roche
We assess the heterogeneous impact of economic downturns on individuals’ decisions to bring high-technology ideas to the market in the form of new ventures. We thereby examine how worsening labor market conditions influence individuals’ opportunity costs of starting... View Details
Keywords: Necessity Entrepreneurship; Economic Conditions; Recessions; High-tech Startups; Opportunity Costs; Entrepreneurship; Economic Slowdown and Stagnation; Business Startups; Information Technology; Performance; Labor
Citation
Find at Harvard
Related
Conti, Annamaria, and Maria P. Roche. "Lowering the Bar? External Conditions, Opportunity Costs, and High-Tech Startup Outcomes." Organization Science 32, no. 4 (July–August 2021): 965–986.
  • 15 Sep 2010
  • Working Paper Summaries

From Bench to Board: Gender Differences in University Scientists’ Participation in Commercial Science

Keywords: by Waverly W. Ding, Fiona Murray & Toby E. Stuart; Biotechnology
  • October 2012
  • Case

GSK's Acquisition of Sirtris: Independence or Integration? (Abridged)

By: Toby Stuart and James Weber
An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science.... View Details
Keywords: Mergers and Acquisitions; Resource Allocation; Organizational Change and Adaptation; Organizational Culture; Organizational Structure; Research and Development; Science-Based Business; Integration
Citation
Educators
Purchase
Related
Stuart, Toby, and James Weber. "GSK's Acquisition of Sirtris: Independence or Integration? (Abridged)." Harvard Business School Case 813-028, October 2012.
  • May 2016
  • Case

AbbVie

By: Kevin Schulman, Laura Little, Samyukta Mullangi and Stephen Schleicher
This case focuses on the impact of a novel regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging biosimilars... View Details
Keywords: Pharmaceutical Company; M&A Valuation; AbbVie; Health Care; Health Care and Treatment; Pharmaceutical Industry; Health Industry; United States
Citation
Educators
Purchase
Related
Schulman, Kevin, Laura Little, Samyukta Mullangi, and Stephen Schleicher. "AbbVie." Harvard Business School Case 316-095, May 2016.
  • 2008
  • Chapter

The Evidence Does Not Speak for Itself: Expert Witnesses and the Organization of DNA-Typing Companies

By: Arthur A. Daemmrich
During the past 15 years, new biotechnology companies have promoted DNA typing as a sophisticated criminal and paternity identification technique. Private testing laboratories produce results that link individuals with crime scenes and fathers to their children.... View Details
Keywords: Governing Rules, Regulations, and Reforms; Courts and Trials; Organizational Structure; Practice; Genetics; Science-Based Business; Trust; Commercialization; Vertical Integration
Citation
Related
Daemmrich, Arthur A. "The Evidence Does Not Speak for Itself: Expert Witnesses and the Organization of DNA-Typing Companies." Chap. 12 in Law and Science. Vol. 1, edited by Susan S. Silbey, 367–398. England: Ashgate Publishing, 2008.
  • January 2011 (Revised July 2012)
  • Case

Arcadia Biosciences: Seeds of Change (Abridged)

By: Arthur A. Daemmrich
Arcadia Biosciences is seeking to introduce genetically modified rice to China that will lower farmers' costs and generate environmental benefits through reduced greenhouse gas emissions. The case describes challenges facing this small agricultural biotechnology... View Details
Keywords: Plant-Based Agribusiness; Intellectual Property; Genetics; Environmental Sustainability; Science-Based Business; Climate Change; Biotechnology Industry; Biotechnology Industry; China
Citation
Educators
Purchase
Related
Daemmrich, Arthur A. "Arcadia Biosciences: Seeds of Change (Abridged)." Harvard Business School Case 711-050, January 2011. (Revised July 2012.)
  • 2010
  • Working Paper

Venture Capital Investment in the Clean Energy Sector

By: Shikhar Ghosh and Ramana Nanda
We examine the extent to which venture capital is adequately positioned for the rapid commercialization of clean energy technologies in the United States. While there are several startups in clean energy that are well-suited to the traditional venture capital... View Details
Keywords: Business Startups; Energy Generation; Venture Capital; Investment; Governing Rules, Regulations, and Reforms; Technological Innovation; Competition; Energy Industry; Green Technology Industry; United States
Citation
Read Now
Related
Ghosh, Shikhar, and Ramana Nanda. "Venture Capital Investment in the Clean Energy Sector." Harvard Business School Working Paper, No. 11-020, August 2010.
  • 18 May 2010
  • First Look

First Look: May 18

http://www.hbs.edu/research/pdf/10-095.pdf   Cases & Course MaterialsMonsanto: Helping Farmers Feed the World David E. Bell, Carin-Isabel Knoop, and Mary ShelmanHarvard Business School Case 510-025 Monsanto has led the effort to bring View Details
Keywords: Martha Lagace
  • March 2020
  • Article

Organizing Knowledge Production Teams Within Firms for Innovation

By: Vikas A. Aggarwal, David H. Hsu and Andy Wu
How should firms organize their pool of inventive human capital for firm-level innovation? While access to diverse knowledge may aid knowledge recombination, which can facilitate innovation, prior literature has focused primarily on one way of achieving that: diversity... View Details
Keywords: Knowledge Recombination; Organization Design; Team Boundary; Innovation; Knowledge Sharing; Diversity; Innovation and Invention; Groups and Teams; Human Capital; Organizational Design
Citation
Read Now
Related
Aggarwal, Vikas A., David H. Hsu, and Andy Wu. "Organizing Knowledge Production Teams Within Firms for Innovation." Art. 1. Strategy Science 5, no. 1 (March 2020): 1–16. (Lead article.)
  • Article

Extending the Role of Headquarters Beyond the Firm Boundary: Entrepreneurial Alliance Innovation

By: Jaeho Kim and Andy Wu
Prior research on corporate headquarters (CHQ) characteristics identifies the impact of CHQ location and composition on the innovation outcomes of internal subsidiaries. However, given that external strategic alliances with high-tech entrepreneurial firms represent a... View Details
Keywords: Alliance; Innovation; Corporate Headquarters; Geographic Proximity; Entrepreneurship; Corporate Strategy; Alliances; Joint Ventures; Innovation and Invention; Business Headquarters; Geographic Location
Citation
Read Now
Related
Kim, Jaeho, and Andy Wu. "Extending the Role of Headquarters Beyond the Firm Boundary: Entrepreneurial Alliance Innovation." Art. 15. Special Issue on Corporate Headquarters. Journal of Organization Design 8 (2019): 1–35.
  • March 2016
  • Article

Environmental Demands and the Emergence of Social Structure: Technological Dynamism and Interorganizational Network Forms

By: Adam Tatarynowicz, Maxim Sytch and Ranjay Gulati
This study investigates the origins of variation in the structures of interorganizational networks across industries. We combine empirical analyses of existing interorganizational networks in six industries with an agent-based simulation model of network emergence.... View Details
Keywords: Interorganizatonal Relationships; Social Networks; Network Emergence; Interorganizational Networks; Information Technology; Networks; Organizational Structure; Social and Collaborative Networks; Social Media
Citation
Find at Harvard
Related
Tatarynowicz, Adam, Maxim Sytch, and Ranjay Gulati. "Environmental Demands and the Emergence of Social Structure: Technological Dynamism and Interorganizational Network Forms." Administrative Science Quarterly 61, no. 1 (March 2016): 52–86.
  • September 2020
  • Case

Minerva 2004: Discovery

By: John R. Wells and Benjamin Weinstock
After nearly five years in operation, Doctor Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), was reflecting on the company’s next steps. In a few short years, she and her small team had managed to develop a nanoparticle process for... View Details
Keywords: Entrepreneurship; Financing and Loans; Strategy; Decision Choices and Conditions; Biotechnology Industry
Citation
Educators
Purchase
Related
Wells, John R., and Benjamin Weinstock. "Minerva 2004: Discovery." Harvard Business School Case 721-389, September 2020.
  • 22 Apr 2009
  • Working Paper Summaries

Where is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location

Keywords: by Arthur Daemmrich; Pharmaceutical
  • October 2022 (Revised May 2023)
  • Case

Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues

By: Aiyesha Dey, Jonas Heese, Suraj Srinivasan and Annelena Lobb
Ginkgo Bioworks, a synthetic biology company based in Boston, Massachusetts, faced divergent views on its revenue possibilities and accounting practices. After a report emerged accusing it of fraudulent accounting and lack of innovation, its share price plunged. But... View Details
Keywords: Fraud Allegations; Revenue; Reports; Accounting Audits; Innovation and Management; Investment; Biotechnology Industry; Boston
Citation
Educators
Purchase
Related
Dey, Aiyesha, Jonas Heese, Suraj Srinivasan, and Annelena Lobb. "Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues." Harvard Business School Case 123-037, October 2022. (Revised May 2023.)
  • ←
  • 7
  • 8
  • …
  • 22
  • 23
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.